Table 1.

Characteristics of CLL patients with IGLV3-21^R110 mutation

Patient	Sex	Age range	Treatment	del17q	CDR3 (aa)	IGHV	IGHD	IGHJ	IGHV status
CLL001	m	n/a	no	no	CALDRDGMDVW	IGHV3-69-1	IGHD3-22	IGHJ6	M
CLL010	m	n/a	no	no	CAVDRNGMDVW	IGHV3-21	IGHD5-18	IGHJ6	M
CLL054	m	n/a	yes	no	CARDTHDTNGYPRWYYGLDVW	IGHV3-11	IGHD3-22	IGHJ6	M
CLL062	m	n/a	yes	no	CANGGGDGEYDYW	IGHV4-39	IGHD3-10	IGHJ4	M
CLL162	m	50–60	no	no	CARGVPRPHW	IGHV3-48	IGHD1-14	IGHJ4	M
CLL306	m	60–70	no	no	CARDLYYYDSSGYYSGFFDYW	IGHV1-46	IGHD3-22	IGHJ4	UM
CLL350	f	70–80	yes	no	CARDVVDYVWGSYLRAFDIW	IGHV1-69	IGHD3-16	IGHJ3	UM
CLL362	f	60–70	yes	no	CARDQVAVAGCFDYW	IGHV4-61	IGHD6-19	IGHJ4	M
CLL374	m	60–70	yes	no	CARDFVEPGYW	IGHV3-48	IGHD6-13	IGHJ5	M
CLL381	f	60–70	yes	no	CARGAGAGDYW	IGHV3-48	IGHD6-13	IGHJ4	M
CLL385	m	50–60	yes	no	CARDVGGDNSGAFDIW	IGHV2-26	IGHD2-21	IGHJ3	UM
CLL401	m	70–80	yes	no	CARDQNTMDVW	IGHV3-21		IGHJ6	UM
CLL424	f	50–60	yes	no	CARPCYDDNSDAFDIW	IGHV3-7	IGHD3-22	IGHJ3	UM
CLL425	f	50–60	yes	no	CARVENDGGYCSGGSCYPIW	IGHV3-48	IGHD2-15	IGHJ4	M
CLL435	m	60–70	no	no	CARDPGVVAATDSAIW	IGHV3-48	IGHD2-15	IGHJ4	M
CLL438	m	80–90	yes	no	CARDQNAMDVW	IGHV3-21		IGHJ6	M
CLL442	f	70–80	yes	no	CVKGGPGDGGNPFDPW	IGHV4-34	IGHD4-23	IGHJ5	UM

f female, m male, n/a not available, aa amino acid, M IGHV mutated, UM IGHV unmutated.